Thrivent Financial for Lutherans Sells 89,852 Shares of Illumina, Inc. $ILMN

Thrivent Financial for Lutherans decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 13.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 600,691 shares of the life sciences company’s stock after selling 89,852 shares during the period. Thrivent Financial for Lutherans’ holdings in Illumina were worth $78,794,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Creative Capital Management Investments LLC lifted its stake in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in Illumina in the 4th quarter valued at approximately $26,000. TD Waterhouse Canada Inc. bought a new stake in Illumina in the 4th quarter valued at approximately $26,000. Laurel Wealth Advisors LLC bought a new stake in Illumina in the 4th quarter valued at approximately $26,000. Finally, Activest Wealth Management lifted its stake in Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.5%

Shares of Illumina stock opened at $142.54 on Friday. Illumina, Inc. has a 12-month low of $78.55 and a 12-month high of $155.53. The stock has a market cap of $21.57 billion, a P/E ratio of 25.92, a P/E/G ratio of 2.37 and a beta of 1.42. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The business’s 50 day moving average is $128.58 and its 200-day moving average is $129.52.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business posted $0.97 EPS. The business’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ILMN shares. Barclays boosted their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday. Piper Sandler cut their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Finally, Stifel Nicolaus upped their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $137.75.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Keith A. Meister sold 225,067 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total value of $32,758,501.85. Following the transaction, the director directly owned 3,604,441 shares in the company, valued at $524,626,387.55. The trade was a 5.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 332,530 shares of company stock valued at $48,303,655. 2.90% of the stock is owned by insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.